Pharmaust Limited (AU:NUZ) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neurizon Therapeutics Limited, a biotech firm focused on neurodegenerative disease treatments, has updated its Securities Trading Policy, as announced on the ASX. The company is actively advancing its lead drug candidate, NUZ-001, which targets ALS, the most prevalent form of motor neurone disease. This update aligns with Neurizon’s commitment to accelerating treatment access and exploring broader applications for its drug.
For further insights into AU:NUZ stock, check out TipRanks’ Stock Analysis page.